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Based on the crystal structure of LeuTAa, a bacterial homo-
logue to the Na+/Cl--dependent neurotransmitter trans-
porters (SLC6 family) from Aquifex aeolicus, it was
proposed that inhibitors of the serotonin and norepine-
phrine transporters (i.e., tricyclic antidepressants, TCAs)
bind in the outer vestibule of the transporter and thus
occlude access of the substrate to the substrate binding
site. This model predicts that inhibitors and substrates are
bound to different sites and is inconsistent with the com-
petitive inhibition of TCA binding by substrate. We sur-
mised that the binding sites overlapped and tested this
conjecture by using carbamazepine as a ligand for the
human serotonin transporter (hSERT). The underlying
rationale is the fact that carbamazepine an analogue of
imipramine is devoid of the aliphatic side chain. As
expected, carbamazepine competes for binding of
[3H]imipramine (and blocks uptake of serotonin medi-
ated by hSERT). However, in the presence of car-
bamazepine, hSERT is still capable of binding substrates
such as serotonin and MPP+ (1-methyl-4-phenylpyridin-
ium); this was demonstrated in experiments with
[3H]imipramine as the radioligand, where the slope of the
Dixon plot for serotonin and MMP+ was increased upon
addition of carbamazepine. In contrast, addition of car-
bamazepine to compounds capable of inducing transport
reversal (p-chloro-amphetamine = PCA, 3,4-methylene-
dioxymethamphetamine = MDMA) invariably gave paral-
lel shift in the Dixon plot. Based on these observations, we
conclude that (i) the ring of tricyclic antidepressants does
not occupy the substrate binding site, and that (ii) releas-
ers induce a conformation, which precludes their simulta-
neous binding together with of transport inhibitors,
resulting in competitive inhibition.
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